Related Experiment Video

Updated: Jan 27, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.6K

First-line tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer: a network meta-analysis

Marscha S Holleman1,2, Harm van Tinteren3, Harry Jm Groen4

  • 1Erasmus School of Health Policy and Management, Erasmus University Rotterdam, Rotterdam, the Netherlands, holleman@eshpm.eur.nl.

Oncotargets and Therapy
|March 14, 2019
PubMed
Abstract

Insights

Osimertinib demonstrates superior efficacy and favorable toxicity compared to other first-line epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) for non-small-cell lung cancer (NSCLC) patients with EGFR mutations. This network meta-analysis suggests osimertinib as a preferred treatment option.

Area of Science:

  • Oncology
  • Pharmacology
  • Clinical Trials

Background:

  • Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) show efficacy in EGFR-mutated non-small-cell lung cancer (NSCLC).
  • A comparative meta-level analysis of efficacy and toxicity among first-line EGFR-TKIs was previously lacking.

Purpose of the Study:

  • To conduct a network meta-analysis (NMA) comparing the efficacy and toxicity of five first-line EGFR-TKIs.
  • To provide an overall view of treatment outcomes for patients with EGFR-mutated NSCLC.

Main Methods:

  • Systematic review of randomized controlled trials.
  • Bayesian network meta-analysis synthesizing data on progression-free survival (PFS), overall survival (OS), objective response rate (ORR), and adverse events.
  • Analysis included 13 trials with 3,539 patients.

Main Results:

  • Osimertinib showed potentially superior efficacy for PFS and OS compared to other TKIs.
  • Afatinib and osimertinib demonstrated a trend towards higher ORR.
  • Afatinib and dacomitinib were associated with a high risk of diarrhea and rash; erlotinib, gefitinib, and osimertinib had a moderate risk.

Conclusions:

  • Osimertinib exhibits favorable efficacy (PFS, OS) in first-line treatment for EGFR-mutated NSCLC.
  • Gefitinib, erlotinib, and osimertinib were associated with fewer toxicities.
  • Osimertinib is indicated as a preferable first-line TKI for patients with activating EGFR-mutated NSCLC.
Keywords:
EGFR-TKIafatiniberlotinibgefitinibnetwork meta-analysisosimertinib

More Related Videos

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

8.3K
A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

10.6K

Related Concept Videos

Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
18.4K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
506
Protein Kinases and Phosphatases02:54

Protein Kinases and Phosphatases

Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
15.1K
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
14.9K
Mutations01:39

Mutations

Overview
94.4K
Viral Mutations00:36

Viral Mutations

A mutation is a change in the sequence of bases of DNA or RNA in a genome. Some mutations occur during replication of the genome due to errors made by the polymerase enzymes that replicate DNA or RNA. Unlike DNA polymerase, RNA polymerase is prone to errors because it is not capable of “proofreading” its work. Viruses with RNA-based genomes, like HIV, therefore accrue mutations faster than viruses with DNA-based genomes. Because mutation and recombination provide the raw material...
39.8K